AI Medical Technology

AI Medical Technology is a Stockholm company whose product, Dermalyser, is a CE marked medical device app that analyzes dermatoscopic images of skin lesions and returns decision support for suspected melanoma in about five seconds. A clinician attaches a compatible dermatoscope to a smartphone, photographs the lesion and receives the assessment during the consultation, so a decision about referral can be made while the patient is still in the room. It is available only to licensed healthcare professionals: general practitioners and primary care physicians in particular, along with dermatologists, hospital and clinic staff and occupational health providers. The company frames the product as an assistant rather than a replacement, with the clinician always making the final diagnosis. Published validation figures include an AUC of 96 percent, sensitivity of 95 percent and specificity of 85 percent for melanoma detection, and a negative predictive value above 99 percent for ruling out malignancy; the vendor also reports up to 56 percent cost savings and 79 percent fewer referrals in its studies. The device is certified under EU MDR 2017/745, the company holds ISO 13485:2016, and validation covers Fitzpatrick skin types I to IV. Pricing is not published. Clinics are asked to book a demo. Dermalyser is a regulated medical device with European certification, so availability depends on jurisdiction, and the company works with Karolinska Institutet, Linköping University and Sahlgrenska Hospital on its clinical research.